GlassScriptPhysician profile
Hector Fabio Rivera
NPI 1609194265
$4,839.75
in general payments reported to CMS, 2019-2025
25 companies · $529 in 2025
The $529 reported for 2025 was less than what a typical Interventional Cardiology provider received nationally (typical 2025 total: $1,092).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,221 · 2020: $714 · 2021: $850 · 2022: $1,258 · 2023: $132 · 2024: $136 · 2025: $529.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $797.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $796.86 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Biotronik INC. | $687.32 | 2019 | |
| Abbott Laboratories | $540.75 | 2019-2025 | Jot Dx |
| Medtronic, INC. | $459.99 | 2021-2022 | |
| Boston Scientific Corporation | $425.01 | 2021-2025 | Watchman, Watchman Access System, Farapulse |
| Inari Medical, INC. | $422.22 | 2022 | |
| Zoll Services LLC (A/K/A Zoll Lifecor Corp) | $397.00 | 2019-2025 | Lifevest |
| Janssen Pharmaceuticals, INC | $351.98 | 2019-2024 | Xarelto |
| Medtronic Vascular, INC. | $225.66 | 2019-2020 | |
| Philips North America LLC | $211.97 | 2022-2025 | Ambulatory Monitoring & Diagnostics Undivided |
| Astrazeneca Pharmaceuticals LP | $147.14 | 2021-2024 | |
| Pfizer INC. | $133.90 | 2019-2025 | |
| Penumbra, INC. | $133.00 | 2020 | |
| Lexicon Pharmaceuticals, INC. | $115.92 | 2023 | Inpefa |
| Akcea Therapeutics, INC. | $103.43 | 2019-2021 | |
| Livanova USA, INC. | $76.79 | 2019 |
Show all 25 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novartis Pharmaceuticals Corporation | $66.81 | 2021-2023 | |
| Amgen INC. | $58.92 | 2019-2025 | Repatha |
| Asahi Intecc USA, INC. | $53.85 | 2022 | |
| E.R. Squibb & Sons, L.L.C. | $49.02 | 2025 | Eliquis, Camzyos |
| Terumo Medical Corporation | $47.61 | 2022 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $39.34 | 2024-2025 | Jardiance |
| Becton, Dickinson and Company | $33.57 | 2025 | Bd Nexiva Diffusics |
| Merck Sharp & Dohme LLC | $23.57 | 2025 | Verquvo |
| Bayer Healthcare Pharmaceuticals INC. | $20.83 | 2025 | |
| Astellas Pharma US INC | $14.15 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Hector Rivera listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.